ArticleCureus2026
Assessing Cognitive Responses and Serum Vitamin B₁₂ Levels in Newly Diagnosed Type 2 Diabetes Mellitus Patients Treated With Metformin: A Prospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Type 2 diabetes mellitus (T2DM) is associated with cognitive impairment, and metformin, the first-line pharmacotherapy, has been linked to vitamin B₁₂ deficiency with potential neurological consequences. Objective evidence linking early metformin-induced changes in vitamin B₁₂ levels to cognitive function remains limited, particularly in Indian populations. Objectives To evaluate changes in serum vitamin B₁₂ status and cognitive function, assessed using P300 event-related potentials (ERPs), after six months of metformin therapy in newly diagnosed T2DM patients. Methods This prospective observational study included 52 adults (18-60 years) with newly diagnosed T2DM who were initiated on metformin monotherapy. Baseline and six-month assessments included serum vitamin B₁₂, homocysteine, methylmalonic acid (MMA), HbA1c, and cognitive evaluation using auditory oddball P300 ERPs. Changes over time were analyzed using the Wilcoxon signed-rank test, and correlations were assessed using Spearman's coefficient. Results After six months, blood sugar control improved significantly. The HbA1c level decreased from 7.8 (6.9-8.9) to 7.2 (6.5-8.1) (p = 0.001). However, serum vitamin B₁₂ levels decreased significantly, from 506.7 (347.3-613.5) to 485.0 (332.4-592.0) (p < 0.001). At the same time, homocysteine and MMA levels increased. Homocysteine increased from 16.5 (10.1-23.9) to 17.2 (10.8-25.0) μmol/L (p < 0.001), suggesting the development of functional vitamin B₁₂ deficiency. Additionally, P300 latency increased significantly at the frontal, central, and parietal electrode sites (p < 0.001), indicating slower cognitive processing. Although vitamin B₁₂ levels decreased, no statistically significant correlation was found between serum vitamin B₁₂ levels and P300 latency. Conclusion In newly diagnosed Indian patients with type 2 diabetes mellitus, six months of metformin therapy improved blood sugar control but was associated with early signs of functional vitamin B₁₂ deficiency and slower cognitive processing, as indicated by increased P300 latency. These results highlight the importance of regular monitoring of vitamin B₁₂ status, including functional markers like homocysteine and MMA. Early detection and correction of vitamin B₁₂ deficiency may help preserve cognitive function and support better long-term outcomes in patients on metformin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.